Additionally, the FLAURA study presented the third-generation EGFR-TKI, osimertinib, which displayed better PFS and OS than first-generation EGFR-TKIs in NSCLC patients with EGFR mutation12,13. This evidence concerns the gene EGFR and non-small cell lung carcinoma.